Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 14:12:410.
doi: 10.1186/1471-2407-12-410.

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

Peter J Mazzone  1 , Hardeep Rai, Mary Beukemann, Meng Xu, Anil Jain, Madhu Sasidhar
Affiliations

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

Peter J Mazzone et al. BMC Cancer. .

Abstract

Background: Metformin and the thiazolidinediones (TZDs) may have a protective effect against the development of lung cancer.

Methods: Patients with diabetes mellitus (DM) were identified from the electronic medical records of the Cleveland Clinic. Diabetics with lung cancer were identified then verified by direct review of their records. Control subjects were matched with cancer subjects 1:1 by date of birth, sex, and smoking history. The frequency and duration of diabetic medication use was compared between the groups. The cancer characteristics were compared between those with lung cancer who had and had not been using metformin and/or a TZD.

Results: 93,939 patients were identified as having DM. 522 lung cancers in 507 patients were confirmed. The matched control group was more likely to have used metformin and/or a TZD (61.0% vs. 41.2%, p < 0.001 for any use; 55.5% vs. 24.6%, p < 0.001 for >24 months vs. 0-12 months). In the group with lung cancer, those who had used metformin alone had a different histology distribution than those who received neither metformin nor a TZD, were more likely to present with metastatic disease (40.8% vs. 28.2%, p = 0.013), and had a shorter survival from the time of diagnosis (HR 1.47, p < 0.005).

Conclusions: The use of metformin and/or the TZDs is associated with a lower likelihood of developing lung cancer in diabetic patients. Diabetics who develop lung cancer while receiving metformin may have a more aggressive cancer phenotype.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival analysis of patients with DM and lung cancer.A. Those receiving metformin and/or a TZD versus those who were not. B. Those receiving metformin alone versus those receiving neither metformin nor a TZD. C. Those receiving a TZD alone versus those receiving neither metformin nor a TZD.
See this image and copyright information in PMC

References

    1. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95:470–478. doi: 10.1093/jnci/95.6.470. - DOI - PubMed
    1. Spitz MR, Hong WE, Amos CI, Wu X, Schabath MB, Dong Q, Shete S, Etzel CJ. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99:715–726. doi: 10.1093/jnci/djk153. - DOI - PubMed
    1. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, Field JK. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–276. doi: 10.1038/sj.bjc.6604158. - DOI - PMC - PubMed
    1. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, Riley TL, Commins J, Oken MM, Berg CD, Prorok PC. Lung cancer risk prediction: Prostate, lung, colorectal and ovarian cancer screening trial modes and validation. J Natl Cancer Inst. 2001;103:1058–1068. - PMC - PubMed
    1. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, Hong WK. An expanded risk prediction model for lung cancer. Cancer Prev Res. 2008;1:250–254. doi: 10.1158/1940-6207.CAPR-08-0060. - DOI - PMC - PubMed